GlaxoSmithKline Pharmaceuticals (GSK) reported a 35.17% increase in net profit for the quarter ending March 2025, compared to the same period last year. Net sales, including other income, grew by 4.79% to Rs 974.37 crore, while operating profit rose by 29.51% to Rs 333.19 crore due to improved profit margins. Raw material costs decreased significantly, falling from 20% of sales to 11.2%, and employee costs were reduced from 16.89% to 14.87%.
Other income also saw a notable increase of 36.37%, reaching Rs 40.68 crore. The company reduced its debt from Rs 18.67 crore to Rs 9.95 crore and saw a rise in cash and investments, with cash growing to Rs 1,403.52 crore and investments increasing to Rs 1,118.25 crore.
For the full year, GSK’s sales grew by 8.56% to Rs 3,749.21 crore, and its operating profit margin improved to 31.40%, driving a 29.57% rise in operating profit to Rs 1,177.36 crore. Net profit attributable to the owners surged by 57.23%, reaching Rs 927.58 crore. GSK’s cash flow from operations saw a significant increase to Rs 1,289.91 crore, compared to Rs 582.00 crore the previous year.
Also See: Q4 Results: Dr. Reddy’s Net profit rises 22% to ₹1,594 cr & Declares Final Dividend
The company also announced a final dividend of Rs 42 per share for the year, with the record date set for May 30, 2025. In a statement, Mr. Bhushan Akshikar, Managing Director of GSK, credited the growth to a diverse portfolio of medicines, vaccines, and specialties, alongside enhanced healthcare professional engagement and digital initiatives. Key brands like Augmentin, Calpol, Ceftum, and Shingrix played a significant role, and GSK plans to continue focusing on innovative oncology treatments in the upcoming year.
